Motor Neurone Disease Adaptive Trial Testing Amantadine and Tacrolimus Treatments
A Multi-Arm Randomized Study for Adults With ALS and Related Motor Neuron Diseases
Led by University of Edinburgh · Updated on 2026-03-04
1150
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether certain approved drugs can slow the progression and improve survival in people with motor neuron disease MND, including amyotrophic lateral sclerosis and related subtypes. This trial uses a multi-arm adaptive design, allowing new drugs to be added and ineffective ones to be dropped over time. The study began with memantine, trazodone, and placebo arms, with amantadine and tacrolimus added later, and the first two drugs removed due to lack of benefit.
Participants are randomly assigned to one of several groups, including amantadine, tacrolimus, or matching placebos taken once daily as either oral solutions or capsules. The adaptive approach enables evaluation of each drug against placebo efficiently. The trial started in February 2020 and continues recruiting with ongoing adjustments to treatments based on emerging results.
During participation, individuals will be monitored over 18 months with regular assessments including ALS functional rating scales, survival analysis, cognition, respiratory function, clinical staging, anxiety and depression evaluations, quality of life measurements, and safety monitoring. Data collection involves questionnaires and clinical tests to track disease progression and treatment effects, with careful attention to tolerability and adverse events throughout the study period.
CONDITIONS
Brief Title
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
Research Team
P
Professor Chandran
A
Amy Stenson
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed diagnosis of motor neuron disease, including ALS by El Escorial or Gold Coast Criteria, primary lateral sclerosis, or progressive muscular atrophy
Age 18 years or older
Women of childbearing potential must have a negative pregnancy test within 7 days before baseline
Women of childbearing potential and fertile men must use effective contraception from consent until 4 weeks after treatment
Willing and able to follow the trial protocol and complete questionnaires
Provided written informed consent (verbal consent allowed with witness if needed)
You will not qualify if you...
Diagnosis of frontotemporal dementia or significant psychiatric disorder preventing informed consent
Current alcoholism
Active suicidal thoughts as assessed by Columbia-Suicide Severity Rating Scale
Use of other investigational devices or medications
For amantadine arm: manic bipolar disorder, peptic ulcer, active epilepsy, allergy to drug, already taking amantadine
For tacrolimus arm: poorly controlled hypertension or diabetes, certain heart conditions, bleeding or immune disorders, infections, history of hepatitis or malignancy, dehydration risk, allergy or intolerance to tacrolimus or excipients, use of interacting medications, inability to swallow capsules, already taking tacrolimus, recent live vaccine within 4 weeks
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 18 months
Participants receive assigned study drugs once daily as part of the trial intervention.
Regular visits during treatment as scheduled by the study team
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Similar Trials
ALS Translational Research Program studying ALS, Motor Neuron Diseases, and related gene carriers in adults
Study of the Synchron BCI Brain-Computer Interface for Adults with Bilateral Upper-Limb Paralysis or Motor Neuron Disease in Australia
Evaluating Electrical Stimulation to Reduce Facial Pain and Improve Jaw Movement and Oral Health in Adults With ALS and PLS
Motor Neurone Disease Adaptive Trial Testing Amantadine and Tacrolimus Treatments
A Multi-Arm Randomized Study for Adults With ALS and Related Motor Neuron Diseases
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Systematic, comprehensive, evidence-based approach to identify neuroprotective interventions for motor neuron disease: using systematic reviews to inform expert consensus.
Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial.